Autoimmune lymphoproliferative syndrome classification: Difference between revisions
Line 8: | Line 8: | ||
==Classification== | ==Classification== | ||
{| class="wikitable" | |||
|+ | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
|} | |||
The revised [[classification]] of [[ALPS]] is as following | The revised [[classification]] of [[ALPS]] is as following | ||
Line 23: | Line 44: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] |
Revision as of 04:04, 6 August 2021
Autoimmune lymphoproliferative syndrome Microchapters |
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Autoimmune lymphoproliferative syndrome classification On the Web |
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome classification |
FDA on Autoimmune lymphoproliferative syndrome classification |
CDC on Autoimmune lymphoproliferative syndrome classification |
Autoimmune lymphoproliferative syndrome classification in the news |
Blogs on Autoimmune lymphoproliferative syndrome classification |
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: David Teachey, MD [2] Sharmi Biswas, M.B.B.S
Overview
Classification of ALPS is based on the recommendations made by first international ALPS workshop held at National Institutes of Health in 2009.
Classification
The revised classification of ALPS is as following
Previous nomenclature Revised nomenclature Gene Definition
ALPStype IIb CEDS CASP8 Splenomegaly, marginal raised DNT, recurrent infections, germline mutations in caspase 8
ALPS type IV RALD NRAS Autoimmunity, lymphadenopathy and/or splenomegaly, elevated or normal DNTs, somatic mutations in NRAS
DALD DALD Unknown Lymphadenopathy and /or splenomegaly, autoimmunity, normal DNTs, defective in vitro FAS-mediated apoptosis
XLP1 XLP1 SH2D1A Hypogammaglobulinemia, fulminant Epstein- Barr virus infection, or lymphoma